13 (1) In subsections (2) and (3), “proceeding” means a proceeding, (a)  in relation to an action under subsection 2 (1), including an action commenced under the Class Proceedings Act, 1992, or (b)  described in section 11 of this Act. 2019, c. 17, Sched. 2, s. 13 (1). Same (2) Despite any prior agreement that purports to bind the Crown in right of Ontario in relation to compensation arising from an opioid-related wrong, (a)  the Crown in right of Ontario is not barred from commencing or participating in a proceeding; (b)  the evidence that may be brought against a party to the agreement in the course of a proceeding is not limited; and (c)  the liability of, or the amount of compensation payable by, a party to the agreement in relation to an opioid-related wrong that is the subject of a proceeding is not limited. 2019, c. 17, Sched. 2, s. 13 (2). Compensation (3) If an agreement described in subsection (2) has been finalized by receiving the consent of all parties to the agreement and all necessary court approvals, if any, before December 12, 2019, any compensation received by the Crown in right of Ontario under the agreement must be deducted from any compensation received by it as a result of a proceeding. 2019, c. 17, Sched. 2, s. 13 (3); 2023, c. 21, Sched. 9, s. 12. Same (4) No compensation is payable by the Crown in right of Ontario and proceedings must not be commenced or continued to claim compensation from the Crown in right of Ontario or to obtain a declaration that compensation is payable by it as a result of the voiding of an agreement described in subsection (2). 2019, c. 17, Sched. 2, s. 13 (4). Same (5) A declaratory or other order of any court providing that compensation is payable by the Crown in right of Ontario as a result of the voiding of an agreement described in subsection (2) is not enforceable against the Crown in right of Ontario. 2019, c. 17, Sched. 2, s. 13 (5). Section Amendments with date in force (d/m/y) 2023, c. 21, Sched. 9, s. 12 - 04/12/2023 14 Omitted (provides for amendments to this Act). 15 Omitted (amends, repeals or revokes other legislation). 16 Omitted (provides for coming into force of provisions of this Act). 17 Omitted (enacts short title of this Act). Schedule 1 1 A product that contains any of the following drugs or active ingredients is an opioid product for the purposes of this Act: 1.  Anileridine. 2.  Buprenorphine, including but not limited to buprenorphine hydrochloride. 3.  Butorphanol, including but not limited to butorphanol tartrate. 4.  Codeine, except for those products referred to in subsection 36 (1) of the Narcotic Control Regulations
(Canada), including but not limited to codeine phosphate. 5.  Diacetylmorphine. 6.  Fentanyl, including but not limited to fentanyl citrate. 7.  Hydrocodone, including but not limited to hydrocodone bitartrate. 8.  Hydromorphone, including but not limited to hydromorphone hydrochloride. 9.  Levorphanol. 10.  Meperidine, including but not limited to meperidine hydrochloride. 11.  Methadone, including but not limited to methadone hydrochloride. 12.  Morphine, including but not limited to morphine hydrochloride and morphine sulfate. 13.  Nalbuphine. 14.  Normethadone, including but not limited to normethadone hydrochloride. 15.  Opium, including but not limited to opium and belladonna. 16.  Oxycodone, including but not limited to oxycodone hydrochloride. 17.  Oxymorphone, including but not limited to oxymorphone hydrochloride. 18.  Pentazocine, including but not limited to pentazocine hydrochloride and pentazocine lactate. 19.  Propoxyphene. 20.  Remifentanil. 21.  Sufentanil. 22.  Tapentadol, including but not limited to tapentadol hydrochloride. 23.  Tramadol, including but not limited to tramadol hydrochloride. 2019, c. 17, Sched. 2, Schedule 1; 2023, c. 21, Sched. 9, s. 13. Section Amendments with date in force (d/m/y) 2023, c. 21, Sched. 9, s. 13 - 04/12/2023 ______________  Français